Literature DB >> 8204394

Radioimmunoscintigraphy of colorectal cancer with technetium-99m-labeled murine anti-carcinoembryonic antigen monoclonal antibody in athymic nude mice.

N Watanabe1, N Oriuchi, S Sugiyama, M Kuroki, Y Matsuoka.   

Abstract

Technetium-99m(Tc-99m) is an ideal radionuclide for clinical use. A murine monoclonal antibody (Mab) designated F33-104 binds to specific parts of carcinoembyronic antigen (CEA). In the present study, intact Mab F33-104 was labeled with Tc-99m, and the immunoreactivity and biodistribution of Tc-99m-labeled F33-104 were studied in athymic nude mice bearing human colorectal cancer xenografts. Mab F33-104, reduced under optimal conditions, was quickly and stably tagged with Tc-99m without loss of immunoreactivity. Higher tumor uptake of Tc-99m-labeled F33-104 was noted in the biodistribution, resulting in a higher localization index and specific-to-non-specific tumor ratio than those of radioiodinated F33-104. These results suggest the potential of Tc-99m-labeled Mab F33-104 for the radioimmunoimaging of colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8204394     DOI: 10.1007/bf03164983

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  24 in total

1.  Preparation of iodine-131 labelled human growth hormone of high specific activity.

Authors:  W M HUNTER; F C GREENWOOD
Journal:  Nature       Date:  1962-05-05       Impact factor: 49.962

Review 2.  Recent advances in tumour imaging. Use of radiolabelled antitumour antibodies.

Authors:  R H Begent
Journal:  Biochim Biophys Acta       Date:  1985

3.  Reduction-mediated technetium-99m labeling of monoclonal antibodies.

Authors:  S J Mather; D Ellison
Journal:  J Nucl Med       Date:  1990-05       Impact factor: 10.057

Review 4.  Recent developments in the radiolabeling of antibodies with iodine, indium, and technetium.

Authors:  D J Hnatowich
Journal:  Semin Nucl Med       Date:  1990-01       Impact factor: 4.446

5.  Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer.

Authors:  H R Maxon; L E Schroder; S R Thomas; V S Hertzberg; E A Deutsch; H I Scher; R C Samaratunga; K F Libson; C C Williams; J S Moulton
Journal:  Radiology       Date:  1990-07       Impact factor: 11.105

6.  Melanoma localization in nude mice with monoclonal Fab against p97.

Authors:  P L Beaumier; K A Krohn; J A Carrasquillo; J Eary; I Hellström; K E Hellström; W B Nelp; S M Larson
Journal:  J Nucl Med       Date:  1985-10       Impact factor: 10.057

7.  Pharmacokinetics of 99mTc(Sn)- and 131I-labeled anti-carcinoembryonic antigen monoclonal antibody fragments in nude mice.

Authors:  A M Zimmer; J M Kazikiewicz; S T Rosen; S M Spies
Journal:  Cancer Res       Date:  1987-03-15       Impact factor: 12.701

8.  Variations in radioimmunoscintigraphic detection of tumor showed by five monoclonal antibodies to carcinoembryonic antigen.

Authors:  K Kohno; K Nakata; Y Kusumoto; N Ishii; T Kohji; Y Matsuoka; S Nishi; S Nagataki
Journal:  Ann Nucl Med       Date:  1991-07       Impact factor: 2.668

9.  Localization of human osteogenic sarcoma xenografts in nude mice by a monoclonal antibody labeled with radioiodine and indium-111.

Authors:  H Sakahara; K Endo; T Nakashima; M Koizumi; M Kunimatsu; Y Kawamura; H Ohta; T Nakamura; H Tanaka; Y Kotoura
Journal:  J Nucl Med       Date:  1987-03       Impact factor: 10.057

Review 10.  Cancer imaging with CEA antibodies: historical and current perspectives.

Authors:  D M Goldenberg
Journal:  Int J Biol Markers       Date:  1992 Jul-Sep       Impact factor: 2.659

View more
  1 in total

1.  Different biodistribution of 99mTc-labelled chimeric mouse-human monoclonal antibody between athymic mice model and human.

Authors:  N Oriuchi; N Watanabe; S Sugiyama; T Higuchi; K Imai; H Yamanaka; M Hashimoto; H Kanda; K Endo
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.